Analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a ...

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development ...

The average one-year price target for TRACON Pharmaceuticals (NASDAQ:TCON) has been revised to 6.63 / share. This is an increase of 21.88% from the prior estimate of 5.44 dated October 4, 2023.

Tracon stock slumps ~15% after I-Mab gets favorable ruling in arbitration Apr. 25, 2023 6:01 AM ET I-Mab (IMAB) Stock , TCON Stock By: Ravikash Bakolia , SA News Editor AmnajKhetsamtip ...

StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research report report published on Tuesday morning.